A Phase 2 Course Determining Study for Men With Hormone-Naïve Metastatic Prostate Cancer (HNMPCa)
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Apalutamide (Primary) ; Prednisone (Primary) ; Abiraterone acetate
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Sep 2024 Planned End Date changed from 1 Oct 2024 to 11 Oct 2026.
- 27 Sep 2024 Planned primary completion date changed from 1 Oct 2024 to 11 Oct 2026.
- 20 Sep 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.